Unigestion Direct II, our latest direct investment fund, invests in small and mid-market companies whose growth is underpinned by global megatrends. The fund also looks to invest in companies resilient in their own right thanks to strong market positions, management and financials.
Francesco Aldorisio, Head of Direct Investments, discusses the companies within the portfolio, with a special focus on HealthTech BioActives, a Spanish company that has done particularly well during the Covid-19 crisis.
